Seeking Alpha
View as an RSS Feed

Stephen Simpson, CFA  

View Stephen Simpson, CFA's Comments BY TICKER:
ABB, ABT, ACE, ACHN, ACI, ADI, ADM, AEIS, AEO, AES, AET, AEZS, AGCO, AGRO, AGXXF, AHL, ALIM, ALK, ALLAY, ALLRF, ALNY, ALU, AMED, AMRN, AMSG, AMX, ANFI, ANGO, ARAY, ARIA, ARNA, ARQL, ARWR, ASOMY, ATHN, ATK, ATLKF, ATLKY, ATML, ATRC, ATX, AUDC, AUXL, AVD, AVGO, AWH, AXAHF, AXAHY, AXAS, AXLL, AZN, AZPN, B, BA, BAC, BAK, BAM, BAS, BASFY, BBG, BBT, BDX, BIIAF, BIIB, BIP, BLERF, BLUE, BMTI, BMY, BPOP, BRCD, BRCM, BRFS, BRK.B, BRSS, BSFT, BSMX, BSX, BTE, BTU, BUI, C, CAT, CBI, CBST, CBWBF, CCLAY, CE, CELG, CEO, CFX, CHEUY, CIEN, CIG, CJES, CLD, CLDX, CMI, CNAT, CODI, COG, CPHD, CPN, CPPMF, CPST, CR, CRESY, CRHKY, CRWS, CSCO, CSFL, CSII, CVGI, CVV, CVX, CYCC, CYNI, CYTR, CZZ, DAN, DBSDY, DCIN, DE, DGI, DIS, DNDN, DNR, DNSKY, DOV, DVN, DVR, EAC, EGBN, ELGX, ELN, ELP, EMR, ENDP, ENOC, ET, ETE, ETN, ETP, ETRM, EW, EXAS, EXC, EXEL, EZPW, FAST, FCE.A, FCE.B, FCFS, FCX, FEIC, FF, FHN, FIO, FIRE, FLOW, FMX, FNV, FOLD, FONR, FRX, FSM, FST, FSUGY, GALE, GBX, GCTAY, GDOT, GE, GELYY, GILD, GLEKY, GLNCY, GLT, GLW, GMAN, GMED, GNKOQ, GNRC, GRH, GSK, GTLS, GTOMY, HAL, HBIO, HBM, HELE, HLF, HLUYY, HNZ, HOGS, HOLI, HOLX, HRL, HSBC, HSP, HTWR, HURC, HW, HXM, ICUI, IIVI, ILMN, IMGN, ING, INGIY, IOSP, IPGLF, IPGP, IR, ISRG, ITRI, ITW, JCI, JCP, JNJ, JOE, JOY, JPM, JRCCQ, KDN, KEX, KGC, KMTUY, KPELY, KRFT, KUKAY, LABL, LAYN, LECO, LHCG, LIOX, LLY, LMIA, LMNR, LMNX, LND, LNVGY, LPDX, LPX, LSI, LSTMF, LUKOY, LXRX, LYSDY, LZAGY, MAKO, MAOIF, MCD, MCHP, MDLZ, MDT, MET, MIC, MIDD, MJNA, MLNX, MLR, MMP, MNK, MNTX, MOCO, MON, MRK, MRLN, MSCC, MSFT, MSM, MTGRF, MTL, MTNOY, MTSC, MTSN, MTW, MWA, MXWL, NAV, NBIX, NBL, NCR, NGVC, NKTR, NRP, NTP, NUAN, NUE, NUVA, NVDQ, NVO, NVS, NYRSY, OAS, ODFL, OGZPY, OKS, OMER, OMI, OMPI, ONNN, ORAN, ORB, OSUR, OZRK, PACB, PANW, PAY, PB, PBF, PBR, PCL, PCXCQ, PDCE, PF, PFE, PG, PHG, PKD, PLPL, PNC, POWR, PRAA, PRIM, PVD, PXGYF, QBCRF, QSFT, RAVN, RCPT, RFMD, RGLD, RHHBY, RHT, RIGL, RVBD, RXN, S, SAN, SANW, SASR, SBMRY, SCGLY, SEIGF, SGEN, SHG, SHS, SIEGY, SLG, SLNCF, SLTM, SLXP, SNCR, SNMX, SNY, SPLK, SPN, SPW, SSH, SSI, STB, STJ, SUMR, SYK, TC, TCB, TCK, TDW, TEAR, TECH, TEVA, TIS, TITN, TKC, TKMR, TMOAY, TPLM, TQNT, TSM, TTM, TUWOY, TWGP, TWI, TYPE, UNT, UPI, UPL, URG, USB, UTEK, V, VDNRF, VICL, VIVHY, VMEM, VOCS, VOLC, VVUS, WAB, WFT, WIRE, WLFC, WLL, WMB, WMGI, WRB, WSBHF, XLP, XNPT, XPO, XRAY, YARIY, YZC, ZION, ZIOP
Latest  |  Highest rated
  • AstraZeneca Suspends The Buyback: Let The M&A Speculation Commence [View article]
    I think the dividend is pretty safe for the near-term. But clearly Soriot needs to fix this business if that is going to be sustainable.
    Oct 2, 2012. 10:35 AM | Likes Like |Link to Comment
  • AstraZeneca Suspends The Buyback: Let The M&A Speculation Commence [View article]
    Good call on Shire, EquiMan
    Oct 2, 2012. 08:51 AM | Likes Like |Link to Comment
  • AstraZeneca Suspends The Buyback: Let The M&A Speculation Commence [View article]
    I don't think so, Valueplay.

    The corporate chronology here (http://bit.ly/SZlRki) doesn't mention that, and the following quote from a long-ago 10-K seems to be consistent with the timeline:

    "In September 1990, Roche Holdings, Inc. (Roche)
    acquired approximately 60% of the Company's voting stock in a merger transaction (Merger). The common stock Roche acquired in the Merger and redeemable common stock subsequently purchased on the open market represented approximately 65% of the outstanding equity of the Company as of March 13, 1995. "

    As for expensive, Roche paid about 9-10x trailing sales at the time of the deal ... though it's a little harder to analyze since Roche bought about 60% upfront and then bought the rest later at a higher price (during which time Genentech grew a lot).

    Hope that answers your question(s)!
    Oct 2, 2012. 06:57 AM | Likes Like |Link to Comment
  • Is Biotech Getting Too Frothy? Investor Sentiment Suggests Irrational Exuberance [View article]
    Michael - Thanks for the praise.

    No need to feel scourged, though. Where I was/am coming from is that, traditionally, "blockbuster" has meant a drug with $1B in revenue. That doesn't mean that a drug like Rytary isn't important to Impax, but in the lingo of biotech as used amongst the buy- and sell-side it pretty much is assumed to mean $1B.
    Oct 1, 2012. 11:52 PM | Likes Like |Link to Comment
  • AstraZeneca Suspends The Buyback: Let The M&A Speculation Commence [View article]
    Would you kindly quote/identify which analyst is estimating $7/sh of earnings for 2020? Thank you.
    Oct 1, 2012. 08:57 PM | Likes Like |Link to Comment
  • Is Biotech Getting Too Frothy? Investor Sentiment Suggests Irrational Exuberance [View article]
    Thanks Whitehawk
    Oct 1, 2012. 05:44 PM | Likes Like |Link to Comment
  • Is Biotech Getting Too Frothy? Investor Sentiment Suggests Irrational Exuberance [View article]
    David - I'd go with the risk-on/risk-off angle. Exchange rates are too trivial to the financials of biotechs to make that much difference, in my opinion.
    Oct 1, 2012. 05:44 PM | Likes Like |Link to Comment
  • Is Biotech Getting Too Frothy? Investor Sentiment Suggests Irrational Exuberance [View article]
    Fair points, but I'm not sure markets ever trade on fundamentals. What's the quote? In the short term it's a voting machine, but in the long term it's a weighing machine?
    Oct 1, 2012. 04:26 PM | Likes Like |Link to Comment
  • Sony (SNE +2.4%) moves ahead with its plan to take a stake in Olympus (OCPNY.PK) with a ¥50B ($644M) investment for a 11% holding in the embattled company. The two companies will set up a JV to develop new medical equipment as Sony eyes ways to make up for its struggling electronics business. Though the deal was expected, ratings agencies could still have to something more to say about Sony's latest venture. [View news story]
    Not to quibble, but I think that's supposed to be an "M" after the $644, not a "B"...
    Sep 27, 2012. 01:25 PM | 1 Like Like |Link to Comment
  • Here We Go Again With AEterna Zentaris... Again [View article]
    Good idea, Jeremy. Thanks!
    Sep 27, 2012. 11:52 AM | Likes Like |Link to Comment
  • NuVasive Could Do Better, But Will It? [View article]
    There are mechanical (especially the brittleness) and imaging issues (radiolucent) w/ silicon nitride.

    What's more, I don't know that Amedica will be able to profitably manufacture these products (and I don't like their chances of getting differentiated reimbursement in the current environment).

    Silicon nitride, as a technology, could indeed be a significant forward step, but based on the performance seen from Amedica over the past few years, I doubt they'll be the ones to exploit it successfully. Obviously I can't and don't know all the orthos in the country, but a lot of the ones I do know don't like Amedica.
    Sep 27, 2012. 10:46 AM | Likes Like |Link to Comment
  • Is There Room For One More Advanced Melanoma Treatment? [View article]
    Alphie9 - Because dermatologists don't care about, or want, the device, and the company hasn't come close to proving that they can sell any commercially relevant quantity of them.
    Sep 26, 2012. 02:12 PM | 3 Likes Like |Link to Comment
  • SPX: A Complicated Power Play [View article]
    Thanks. I really appreciate that.
    Sep 25, 2012. 05:03 PM | Likes Like |Link to Comment
  • Neurocrine Still Looks Significantly Underrated [View article]
    Relaxin is still in P3. NVS mgmt said (Q2 conf call) that data would be out close to year-end.
    Sep 22, 2012. 08:31 AM | Likes Like |Link to Comment
  • Here We Go Again With AEterna Zentaris... Again [View article]
    Well done, wiesemc. That's not my style (swing trading), but all profits pretty much spend the same.
    Sep 21, 2012. 05:13 PM | Likes Like |Link to Comment
COMMENTS STATS
1,602 Comments
761 Likes